Cellectar Biosciences Inc’s filing revealed that its Chief Operating Officer Longcor Jarrod acquired Company’s shares for reported $8400.0 on Jan 10 ’25. In the deal valued at $0.28 per share,30,000 shares were bought. As a result of this transaction, Longcor Jarrod now holds 83,141 shares worth roughly $24942.3.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. ROTH Capital started covering the stock on September 13, 2019. It rated CLRB as “a Buy”.
Price Performance Review of CLRB
On Monday, Cellectar Biosciences Inc [NASDAQ:CLRB] saw its stock jump 2.06%% to $0.3. Over the last five days, the stock has lost -27.93%. Cellectar Biosciences Inc shares have fallen nearly -88.85% since the year began. Nevertheless, the stocks have fallen -0.40% over the past one year. While a 52-week high of $3.15 was reached on 06/04/25, a 52-week low of $0.22 was recorded on 01/15/25.
Levels Of Support And Resistance For CLRB Stock
The 24-hour chart illustrates a support level at 0.2827, which if violated will result in even more drops to 0.2675. On the upside, there is a resistance level at 0.3106. A further resistance level may holdings at 0.3233.
How much short interest is there in Cellectar Biosciences Inc?
A steep rise in short interest was recorded in Cellectar Biosciences Inc stocks on 2025-05-30, dropping by -0.11 million shares to a total of 1.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 1.56 million shares. There was a decline of -7.6%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 21, 2016 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $2.70 price target.
